World News

The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.

BMS will pay up to USD850 million, structured as USD50 million in upfront and near-term payments combined with USD800 million in regulatory, development, and milestone-based payouts.

The newly developed syringe has been specifically engineered to work seamlessly with Ypsomed’s YpsoMate 5.5 autoinjector platform.

The acquisition adds two key products to BioStem’s portfolio: Neox and Clarix, both cryopreserved amniotic membrane allografts.

The device works by carefully opening the obstructed prostate, providing relief from lower urinary tract symptoms that significantly impact patients’ daily lives.

Pfizer will assume complete responsibility for developing and bringing to market any vaccine products that utilize Matrix-M technology.

Doctors now use these highly realistic training tools to master complex surgical procedures, refine ultrasound diagnostic techniques, and verify the accuracy of CT and MRI imaging equipment.

Dr. Basson joins Variant Bio with more than 25 years of leadership experience spanning academic medicine, global pharmaceutical development, and biotechnology sectors.

President Donald Trump initiated this process exactly one year ago when he signed an executive order on his first day in office in 2025, pointing to what he described as the organization’s “mishandling of the COVID-19 pandemic” and its response to “other global health crises.”

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.